A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation
Open Access
- 28 June 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 13 (7), 975-983
- https://doi.org/10.1002/lt.21117
Abstract
Recurrence of hepatitis C virus (HCV) following liver transplantation (LT) is universal. A subset of these patients develop advanced fibrosis and cirrhosis and it is believed that this leads to increased posttransplantation mortality. The specific aims of this study were to determine the incidence of advanced fibrosis and those factors associated with this process, and to evaluate causes for mortality in patients with recurrent HCV. A total of 227 patients who underwent LT with chronic HCV were monitored prospectively. The mean age of this group at LT was 49.5 yr; 76% were male and 85% were Caucasian. Fibrosis progression was monitored by protocol liver biopsy, initially performed 6 months after LT and then at 6- to 24-month intervals. Advanced fibrosis, defined as the bridging fibrosis or cirrhosis, developed in 1%, 11%, 25%, and 41% of patients after 1, 3, 5, and 6-10 yr, respectively. Acute cellular rejection hepatic steatosis, a persistent elevation in serum alanine aminotransferase and donor-race were associated with the development of advanced fibrosis. In contrast, the development of advanced fibrosis was not affected by the use of interferon prior to undergoing LT, cytomegalovirus disease, or donor age. A total of 60 patients (26%) died over 15 yr of follow-up. Although graft failure accounted for 45% of deaths in patients with advanced fibrosis, this represented only 8% of all deaths in patients with recurrent HCV. Sepsis was the most common cause of death and this was observed with similar frequency in patients who developed advanced fibrosis (45%) and in those with less advanced fibrosis (47%). In conclusion, approximately 41% of patients with recurrent HCV developed advanced fibrosis 6-10 yr after LT. However, complications associated with sepsis, not recurrent cirrhosis, was the most common cause of death in patients with recurrent HCV and this was similar in patients with or without advanced fibrosis. Liver Transpl 13:975–983, 2007. © 2007 AASLD.Keywords
This publication has 38 references indexed in Scilit:
- Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppressionJournal of Hepatology, 2006
- Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infectionHepatology, 2006
- Donor Characteristics Associated with Liver Graft SurvivalTransplantation, 2005
- Fibrosis progression after liver transplantation in patients with recurrent hepatitis CJournal of Hepatology, 2004
- Fibrosis progression after liver transplantation in patients with recurrent hepatitis CJournal of Hepatology, 2004
- Donor age influences 10-year liver graft histology independently of hepatitis C virus infectionJournal of Hepatology, 2004
- Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantationLiver Transplantation, 2004
- Controversies in the management of hepatitis C virus infection after liver transplantationLiver Transplantation, 2003
- Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantationHepatology, 1995
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology, 1981